In September, Congress returns, rarin' to go, from its August recess. Time is short until midterm elections, and the two houses have much unfinished business to get to in time to impress voters. Still unresolved when members adjourned was legislation to reform lobbying practices, regulate immigration, and pass the spending bills that fund the operations of government.
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.